Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas.

Travis WD.

Mod Pathol. 2012 Jan;25 Suppl 1:S18-30. doi: 10.1038/modpathol.2011.150. Review.

2.

Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens.

Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, Falk R, Travis WD.

Am J Surg Pathol. 2002 Sep;26(9):1184-97.

PMID:
12218575
3.

Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases.

Travis WD, Linnoila RI, Tsokos MG, Hitchcock CL, Cutler GB Jr, Nieman L, Chrousos G, Pass H, Doppman J.

Am J Surg Pathol. 1991 Jun;15(6):529-53.

PMID:
1709558
4.

Cytology-based treatment decision in primary lung cancer: is it accurate enough?

Sakr L, Roll P, Payan MJ, Liprandi A, Dutau H, Astoul P, Robaglia-Schlupp A, Loundou A, Barlesi F.

Lung Cancer. 2012 Mar;75(3):293-9. doi: 10.1016/j.lungcan.2011.09.001. Epub 2011 Oct 5.

PMID:
21975144
5.

Large cell neuroendocrine carcinoma of the lung: a histologic and immunohistochemical study of 22 cases.

Jiang SX, Kameya T, Shoji M, Dobashi Y, Shinada J, Yoshimura H.

Am J Surg Pathol. 1998 May;22(5):526-37.

PMID:
9591721
6.

Synchronous primary lung cancers: a multidisciplinary approach in diagnosis.

Kontic M, Stevic R, Stojsic J, Jekic B, Bunjevacki V.

Tumori. 2011 Jul-Aug;97(4):e16-9. doi: 10.1700/950.10414.

7.
8.

Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Bircan A, Bircan S, Kapucuoglu N, Songur N, Ozturk O, Akkaya A.

Pathol Oncol Res. 2010 Dec;16(4):553-61. doi: 10.1007/s12253-010-9259-5. Epub 2010 Mar 28.

PMID:
20349288
9.

[Application of protein markers in combination with ThinPrep bronchial brush cytology in classification of lung cancer subtypes].

Yang Y, Pan QJ, Teng MF, Li ZL, Zhao LL, Han NJ, Gao YN, Cao J.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):616-9. Chinese.

PMID:
19102942
10.

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.

Travis WD, Rekhtman N.

Semin Respir Crit Care Med. 2011 Feb;32(1):22-31. doi: 10.1055/s-0031-1272866. Epub 2011 Apr 15. Review.

PMID:
21500121
11.

Synchronous primary lung cancer presenting with small cell carcinoma and non-small cell carcinoma: diagnosis and treatment.

Hiraki A, Ueoka H, Yoshino T, Chikamori K, Onishi K, Kiura K, Bessho A, Mimoto J, Date H, Ando A, Shimizu N, Harada M.

Oncol Rep. 1999 Jan-Feb;6(1):75-80. Review.

PMID:
9864405
12.

ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.

Pelosi G, Rossi G, Cavazza A, Righi L, Maisonneuve P, Barbareschi M, Graziano P, Pastorino U, Garassino M, de Braud F, Papotti M.

Int J Surg Pathol. 2013 Jun;21(3):229-39. doi: 10.1177/1066896913476750. Epub 2013 Mar 12.

PMID:
23486764
13.

Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers.

Wu M, Szporn AH, Zhang D, Wasserman P, Gan L, Miller L, Burstein DE.

Diagn Cytopathol. 2005 Oct;33(4):223-7.

PMID:
16138374
14.

The use of p63 as an effective immunomarker in the diagnosis of pulmonary squamous cell carcinomas on de-stained bronchial lavage cytological smears.

Uke M, Rekhi B, Ajit D, Jambhekar NA.

Cytopathology. 2010 Feb;21(1):56-63. doi: 10.1111/j.1365-2303.2009.00678.x. Epub 2009 Sep 9.

PMID:
19744186
15.

Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach.

Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH.

Clin Cancer Res. 2010 Jan 15;16(2):610-9. doi: 10.1158/1078-0432.CCR-09-2638. Epub 2010 Jan 12.

16.

The value of cytological diagnosis of small cell lung carcinoma.

Domagała-Kulawik J, Górnicka B, Krenke R, Mich S, Chazan R.

Pneumonol Alergol Pol. 2010;78(3):203-10.

17.

Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.

Pujol JL, Simony J, Laurent JC, Richer G, Mary H, Bousquet J, Godard P, Michel FB.

Cancer Res. 1989 May 15;49(10):2797-802.

18.

Prognostic significance of histopathologic subtype and stage in small cell lung cancer.

Fraire AE, Johnson EH, Yesner R, Zhang XB, Spjut HJ, Greenberg SD.

Hum Pathol. 1992 May;23(5):520-8.

PMID:
1314777
19.

Different expression of mimecan as a marker for differential diagnosis between NSCLC and SCLC.

Zheng CX, Zhao SX, Wang P, Yu HM, Wang CF, Han B, Su B, Xiang Y, Li XS, Li SX, Ma QY, Zhang RX, Wan HY, Song HD.

Oncol Rep. 2009 Nov;22(5):1057-61.

PMID:
19787221
20.

Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Cohen AJ, Bunn PA, Franklin W, Magill-Solc C, Hartmann C, Helfrich B, Gilman L, Folkvord J, Helm K, Miller YE.

Cancer Res. 1996 Feb 15;56(4):831-9.

Supplemental Content

Support Center